Belimumab for the treatment of pediatric patients with lupus nephritis
W Stohl, A Kwok - Expert Opinion on Biological Therapy, 2023 - Taylor & Francis
Introduction The FDA approved the anti-BAFF monoclonal antibody, belimumab, in 2011 for
adult systemic lupus erythematosus (SLE), in 2019 for pediatric SLE, in 2020 for adult lupus …
adult systemic lupus erythematosus (SLE), in 2019 for pediatric SLE, in 2020 for adult lupus …
Belimumab in childhood systemic lupus erythematosus: A review of available data
F Chen, Y Zheng, X Chen, Z Wen, Y Xu… - Frontiers in …, 2022 - frontiersin.org
Introduction Childhood systemic lupus erythematosus (cSLE) is a complex multisystem
autoimmune disease. In 2019, belimumab was approved for the clinical treatment for cSLE …
autoimmune disease. In 2019, belimumab was approved for the clinical treatment for cSLE …
[HTML][HTML] Белимумаб в лечении системной красной волчанки: 20 лет фундаментальных исследований, 10 лет клинической практики
ЕЛ Насонов, ТВ Попкова, АМ Лила - Научно-практическая …, 2021 - cyberleninka.ru
В настоящее время получены веские доказательства фундаментальной роли
патологической активации В-клеток в патогенезе иммуновоспалительных …
патологической активации В-клеток в патогенезе иммуновоспалительных …
Corticosteroid dosing and opioid use are high in patients with SLE and remain elevated after belimumab initiation: a retrospective claims database analysis
JA Birt, J Wu, K Griffing, N Bello, N Princic… - Lupus Science & …, 2020 - lupus.bmj.com
Objectives To investigate corticosteroid and opioid use among patients with SLE and to
examine the impact of belimumab initiation on the use of other SLE therapies. Methods We …
examine the impact of belimumab initiation on the use of other SLE therapies. Methods We …
[HTML][HTML] Anticuerpos monoclonales y el tratamiento del lupus eritematoso sistémico
A Chavarría-Tapia, A Fernández-Corella… - Revista Tecnología en …, 2021 - scielo.sa.cr
El lupus eritematoso sistémico es una enfermedad autoinmune crónica, que implica la
producción de ciertos anticuerpos en todo el cuerpo y la consecuente inflamación de tejidos …
producción de ciertos anticuerpos en todo el cuerpo y la consecuente inflamación de tejidos …
Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I …
Background 300 mg of intravenous anifrolumab every 4 weeks added to standard-of-care
treatment for patients with systemic lupus erythematosus (SLE) reduced disease activity and …
treatment for patients with systemic lupus erythematosus (SLE) reduced disease activity and …
Belimumab 10 years later: how drug positioning has changed
F Ceccarelli, F Natalucci, C Ciancarella… - Immunologic …, 2024 - Springer
We analysed the change in the positioning of belimumab (BLM) in systemic lupus
erythematosus (SLE) treatment in the first decade of real-life use, by providing data about …
erythematosus (SLE) treatment in the first decade of real-life use, by providing data about …
[HTML][HTML] Immunotherapies application in active stage of systemic lupus erythematosus in pregnancy: a case report and review of literature
ZH Xiong, XS Cao, HL Guan… - World Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
BACKGROUND Pregnancy in the setting of systemic lupus erythematosus can worsen the
condition from the stable to active stage, with quality of life and fertility desire being particular …
condition from the stable to active stage, with quality of life and fertility desire being particular …
The controversial role of wellbeing assessment in juvenile idiopathic arthritis
S Santaniello, A Ravelli - The Lancet. Rheumatology, 2021 - pubmed.ncbi.nlm.nih.gov
The controversial role of wellbeing assessment in juvenile idiopathic arthritis The
controversial role of wellbeing assessment in juvenile idiopathic arthritis Lancet Rheumatol …
controversial role of wellbeing assessment in juvenile idiopathic arthritis Lancet Rheumatol …
Efficay and safety of belimumab in lupus patients with hematological involvement in a multicenter prospective cohort study
K BRUSHTULLI - thesis.unipd.it
Abstract Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by a
disfunction of the immune system and widespread inflammation. One common manifestation …
disfunction of the immune system and widespread inflammation. One common manifestation …